# BETA DRUGS LIMITED

**BDL/PKL/SEC/2022**
**27th April, 2022**

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

**SYMBOL-BETA**

**Sub: Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2022 under Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015**

Dear Sir/Madam

Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the company at their meeting held on Wednesday, 27th April, 2022 had considered and approved the Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2022.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following:

1. Management discussion & Analysis
2. Independent Auditor Report of Consolidated Financial Results alongwith Audited Consolidated Financial Results for the half year and year ended on 31st March, 2022.
3. Independent Auditor Report of Standalone Financial Results alongwith Audited Standalone Financial Results for the half year and year ended on 31st March, 2022.
4. Declaration for un-modified opinion on Audited Standalone and Consolidated Financial Results for the half year and year ended on 31st March, 2022.

The meeting of the Board of Directors commenced at 9.00 a.m. and concluded at 2:00 pm.

This is for your information and appropriate dissemination.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

BETA DRUGS LTD. BADDI (H.P.)

Rajni Brar
Company Secretary

**CIN No.:** L24230HP2005PLC028969
**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483
**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196
**Website :-** www.betadrugslimited.com **E-Mail :-** info@betadrugslimited.com

# BETA DRUGS LIMITED

## Management Discussion & Analysis

Beta consolidated revenues from operations for FY22 increased by 58% to Rs 183.84 crores from Rs 116.12crores compared with the same period a year ago. Strong top-line growth was primarily driven by higher Own brand sales, followed by CRAMs and API sales to third parties.

Consolidated EBITDA grew by 72% to Rs 43.5 crores from 25.24 crores compared with the year-ago period. While EBITDA margin expanded to23.6% from21.7%. Overall improvement in EBITDA was on account of higher sales of branded products, exports, and cost rationalization initiatives.

Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.

The company was able to reduce its debtor days to 90 days compared with 106 days while inventory days stood at 45 days as against 50 days a year ago. Beta continues to focus on increasing productivity and gaining efficiencies across the value chain.

The company has become net debt-free.

## Outlook for FY23

Management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years.

The company expects revenues in FY23 to grow at 30% while EBITDA margins are expected to improve further to approximately 24%-24.5%, provided COVID-19 does not cause any further disruptions.

In addition, the company is bringing FTLs, NDDS, PARP inhibitors, and TKIs which will drive growth for many years to come. The company is also expanding its API capabilities by developing new products. Backward integration will further ensure high-quality anti-cancer drugsfor Indian and International patients and helping the company to expand both its presence & margins.

BETA DRUGS LTD. (H.P.)

GSTIN. 04AAFFK0327H1ZT

KALRA RAI & ASSOCIATES
A Peer Review Firm
CHARTERED ACCOUNTANTS

M : +91-98880-66743
Phone - 0172-4640667
E-mail : kalrarai@gmail.com
kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**Independent auditor's report (unmodified opinion) on the half yearly consolidated financial results and annual consolidated financial results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for companies**

**INDEPENDENT AUDITOR'S REPORT**

**TO THE BOARD OF DIRECTORS OF**

Beta Drugs Limited
Village Nandpur, Lodhimajra ROad
Baddi Distt Solan
H.P.-174101

**Report on the Audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying consolidated half yearly financial results for the period ended 31st March, 2022 and consolidated annual financial results of **Beta Drugs Limited** for the year ended 31st March, 2022 (hereinafter referred to as the 'Holding Company") and its subsidiaries **M/s Adley Formulations Private Limited** and **M/s Adley Lab Limited** (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended **31st March, 2022**, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements /financial results/ financial information of the subsidiaries, associates and jointly controlled entities, the aforesaid consolidated financial results:

(i) include the annual financial results of the following entities

a) **Adley Lab Limited**

b) **Adley Formulations Pvt Ltd.**

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the half year ended **31st March, 2022 as well as the year to date results for the period ended 31st March, 2022**.

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008659N

Branch Office Mohali :-
Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082
EMAIL : kalrarai@rediffmail.com
Branch Office Delhi :-
I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803
EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Consolidated Financial Results**

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

**Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate,

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008859N

they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

KALRA RAI & ASSOCIATES
Chartered Accountants
FRN 008859N

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

The consolidated Financial Results include the **audited Financial Results** of **Adley Lab Limited and Adley Formulations Pvt Ltd,** subsidiaries, whose Financial Statements/Financial Results/ financial information reflect Group's share of total assets of Rs. 46,95,58,605.70/- as at **31st March, 2022** , Group's share of total revenue of Rs. 30,37,90,853.33/- and Rs. 58,88,96,264.86/- and Group's share of total net profit/(loss) after tax of Rs. 6,17,14,000.32/- and Rs. 10,58,10,607.20/- for the half year ended **31st March, 2022** and for the period from **1st April, 2021 to 31st March, 2022** respectively, as considered in the consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/ Financial Results/financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

The Financial Results include the results for the half year ended **31st March, 2022** being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the **1st half year** of the current financial year.

**For KALRA RAI & ASSOCIATES.**
**Chartered Accountants**
**(Firm's Registration No. 008859N)**

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008859N

**LAJPAT RAI KALRA**
**(Partner)**
**(Membership Number: 087438)**
**UDIN: 22087438AHWYXN2366**

**Place: Chandigarh**
**Date: 27/04/2022**

**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Audited Consolidated Financial Results for the year ended on 31st March' 2022**

| Particulars | 6 Months Ended on 31/03/2022 (Audited) | Year Ended on 31/03/2022 (Audited) | 6 Months Ended on 31/03/2021 (Audited) | Year Ended on 31/03/2021 (Audited) |
|---|---|---|---|---|
| I. Revenue From Operations | 95,74,19,333.91 | 1,83,83,74,346.40 | 64,74,16,349.47 | 1,16,12,19,137.19 |
| II. Other Income | 30,23,489.47 | 75,68,912.50 | 23,87,251.59 | 49,77,593.92 |
| **III. Total Revenue (I+II)** | **96,04,42,823.38** | **1,84,59,43,258.90** | **64,98,03,601.06** | **1,16,61,96,731.11** |
| IV. Expenses | | | | |
| a) Cost of Materials Consumed | 48,49,34,030.25 | 96,20,72,647.56 | 34,25,27,195.50 | 60,55,46,776.37 |
| b) Purchase of Stock-in-Trade | - | - | - | - |
| c) (Increase)/Decrease in Stock of Finished Goods/WIP | (71,09,940.13) | (1,74,55,548.53) | (2,07,31,060.43) | (1,77,44,801.68) |
| d) Other Manufacturing expenses | 9,03,96,784.64 | 17,77,92,056.82 | 7,59,57,203.99 | 13,40,13,198.85 |
| e) Employee benefit expenses | 8,96,89,281.17 | 15,90,77,509.07 | 6,06,69,098.10 | 10,88,25,357.10 |
| f) Finance Costs | 96,86,061.52 | 1,89,90,952.71 | 1,21,61,735.77 | 2,41,95,981.81 |
| g) Depreciation & amortisation expenses | 3,94,87,087.08 | 7,25,42,401.22 | 3,67,93,008.95 | 6,87,36,201.42 |
| h) Other expenses | 7,29,72,641.58 | 12,99,09,292.90 | 4,82,94,584.49 | 8,31,15,284.55 |
| **Total Expenses** | **78,00,55,946.11** | **1,50,29,29,311.75** | **55,56,71,766.37** | **1,00,66,87,998.42** |
| **V. Profit before exceptional and extraordinary items and tax (III-IV)** | **18,03,86,877.27** | **34,30,13,947.15** | **9,41,31,834.69** | **15,95,08,732.69** |
| **VI.Exceptional Items** | - | - | - | - |
| **VII. Profit before extraordinary items and tax (V-VI)** | **18,03,86,877.27** | **34,30,13,947.15** | **9,41,31,834.69** | **15,95,08,732.69** |
| **VIII.Extraordinary Items** | - | - | - | - |
| **IX. Profit before tax (VII-VIII)** | **18,03,86,877.27** | **34,30,13,947.15** | **9,41,31,834.69** | **15,95,08,732.69** |
| **X.Tax Expenses** | | | | |
| a) Current year tax | 4,81,12,283.59 | 9,50,61,509.95 | 3,18,69,751.24 | 4,70,75,840.42 |
| b) MAT credit/Deferred tax | 15,07,121.76 | (3,23,009.94) | (31,70,760.47) | (48,11,646.39) |
| **XI. Profit (Loss) for the period from continuing operations (IX-X)** | **13,07,67,471.92** | **24,82,75,447.13** | **6,54,32,843.92** | **11,72,44,538.66** |
| **XII.Profit (Loss) from discounting operations** | | | | |
| **XIII. Tax expenses of dicounting operations** | | | | |
| **XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)** | - | - | - | - |
| **XV. Net Profit/(Loss) for the period (XI+XIV)** | **13,07,67,471.92** | **24,82,75,447.13** | **6,54,32,843.92** | **11,72,44,538.66** |
| **XVI. Earning per share** | | | | |
| a) Basic | 13.60 | 25.82 | 6.81 | 12.20 |
| b) Diluted | 13.60 | 25.82 | 6.81 | 12.20 |
| **XVIII. Paid up equity share captial** | **9,61,37,900.00** | **9,61,37,900.00** | **9,61,37,900.00** | **9,61,37,900.00** |
| **Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year** | **82,72,87,694.27** | **82,72,87,694.27** | **58,99,89,268.83** | **58,99,89,268.83** |

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 27th April 2022.

2 The company is engaged in single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

4 The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008859N)

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008859N

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
UDIN: 22087438AHWYXN2366
Place : Chandigarh
Date : 27/04/2022

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO

# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

## Consolidated Statement of Assets & Liabilities for the year ended on 31st March' 2022

| Particulars | As at 31st March' 2022<br>Amount in Rs. | As at 31st March' 2021<br>Amount in Rs. |
|---|---|---|
| **1. EQUITY AND LIABILITIES** | | |
| **(A) Shareholder's Funds** | | |
| (a) Share Capital | 9,61,37,900.00 | 9,61,37,900.00 |
| (b) Reserves and Surplus | 82,72,87,694.27 | 58,99,89,268.83 |
| (c)Money recevied against share warrants | - | - |
| **Sub-total-Shareholders' funds** | **92,34,25,594.27** | **68,61,27,168.83** |
| **(B) Non- Current Liabilities** | | |
| (a) Long-term borrowings | 11,82,61,500.00 | 11,12,99,220.69 |
| (b) Deferred tax liabilities (Net) | - | - |
| (c) Other Long term liabilities | 3,23,96,047.65 | 3,32,81,016.17 |
| (d) Long term Provisions | 1,47,47,479.00 | 1,13,62,417.00 |
| **Sub-total-Non- current liabilities** | **16,54,05,026.65** | **15,59,42,653.86** |
| **(C) Current Liabilities** | | |
| (a) Short-term borrowings | 4,75,42,666.42 | 3,54,05,109.95 |
| (b) Trade Payable | 31,95,19,463.32 | 20,49,37,503.62 |
| (c) Other current liabilities | 8,63,29,640.17 | 7,84,51,082.99 |
| (d) Short-term provisions | 3,63,07,263.36 | 1,41,91,654.11 |
| **Sub-total-current liabilites** | **48,96,99,033.27** | **33,29,85,350.67** |
| **TOTAL - EQUITY AND LIABILITIES** | **1,57,85,29,654.20** | **1,17,50,55,173.37** |
| **2. ASSETS** | | |
| **(A) Non-current assets** | | |
| (a) Fixed assets | | |
| (i) Property, Plant & Equipment | 50,66,77,310.22 | 36,45,47,461.00 |
| (ii) Intangible assets | 4,28,73,439.35 | 3,51,69,926.83 |
| (iii) Capital work-in-progress | - | 2,81,00,988.20 |
| (b) Non Current Investments | 77,89,905.49 | 77,89,905.49 |
| (c) Long Term Loan & Advance | 4,43,02,141.08 | 1,85,28,814.06 |
| (d) Other Non Current Assets | 5,00,000.00 | 3,40,29,279.69 |
| (e) Deferred tax Assets | 67,99,324.01 | 64,76,314.08 |
| **Sub-total-Non-current assets** | **60,89,42,120.15** | **49,46,42,689.35** |
| **(B) Current Assets** | | |
| (a) Inventories | 22,48,14,949.85 | 16,04,25,446.92 |
| (b) Trade receivable | 45,18,18,610.47 | 33,87,64,370.00 |
| (c) Cash and bank balance | 17,32,40,340.97 | 10,42,47,300.46 |
| (d) Short-term loan and advances | 4,47,68,829.69 | 2,42,40,991.86 |
| (e) Other current assets | 7,49,44,803.07 | 5,27,34,374.78 |
| **Sub-total-current assets** | **96,95,87,534.05** | **68,04,12,484.02** |
| **TOTAL - ASSETS** | **1,57,85,29,654.20** | **1,17,50,55,173.37** |

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 27th April 2022
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.
4. The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

**For KALRA RAI AND ASSOCIATES**
Chartered Accountants
**(FRN : 008859N)**

**LAJPAT RAI KALRA**
**PARTNER**
**Membership No. : 087438**
**UDIN: 22087438AHWYXN2366**
**Place : Chandigarh**
**Date : 27/04/2022**

**For and on Behalf of Board of Directors**

**RAHUL BATRA**
**MANAGING DIRECTOR**
**DIN : 02229234**

# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

## Consolidated Cashflow Statement for the year ended on 31st March' 2022

| | Particulars | As at 31 March' 2022 | As at 31 March' 2021 |
|---|---|---|---|
| | | Amount in Rs. | Amount in Rs. |
| A | **CASHFLOW FROM OPERATING ACTIVITIES** | | |
| | **Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)** | **34,30,13,947.15** | **15,95,08,732.69** |
| | Adjustments for non Cash/Non trade items: | | |
| | Depreciation & Amortization Expenses | 7,25,42,401.22 | 6,87,36,201.42 |
| | Finance Cost | 1,89,90,952.71 | 2,41,95,981.81 |
| | Interest received | (45,17,345.97) | (33,44,427.55) |
| | Other inflows/(outflows) of cash | (3,60,31,559.02) | (2,41,72,864.14) |
| | **Operating profits before Working Capital Changes** | **39,39,98,396.09** | **22,49,23,624.23** |
| | **Adjusted For:** | | |
| | (Increase)/Decrease in trade receivables | (11,30,54,240.47) | (1,94,95,819.90) |
| | Increase/(Decrease) in trade payables | 11,45,81,959.70 | 6,00,47,083.92 |
| | (Increase)/Decrease in inventories | (6,43,89,502.93) | (3,69,60,372.54) |
| | Increase/(Decrease) in other current liabilities | 78,78,557.18 | (2,44,08,142.77) |
| | (Increase)/Decrease in short term loans and advances | (2,05,27,837.83) | (96,85,002.61) |
| | (Increase)/Decrease in other current assets | (2,22,10,428.29) | (84,22,955.74) |
| | **Net Changes in working capital** | **(9,77,21,492.64)** | **(3,89,25,209.64)** |
| | **Net cashflow from Operating Activities (A)** | **29,62,76,903.45** | **18,59,98,414.59** |
| B | **CASHFLOW FROM INVESTING ACTIVITIES** | | |
| | Purchase of tangible/intangible assets | (19,42,74,774.76) | (5,75,55,411.97) |
| | Interest received | 45,17,345.97 | 33,44,427.55 |
| | Cash used for Non Current Investments | - | (42,69,312.87) |
| | Cash used for Long Term Loans/Advances | (2,77,90,348.71) | - |
| | **Net cash used in Investing Activities (B)** | **(21,75,47,777.50)** | **(5,84,80,297.29)** |
| C | **CASHFLOW FROM FINANCING ACTIVITIES** | | |
| | Finance Cost | (1,89,90,952.71) | (2,41,95,981.81) |
| | Increase in/(Repayment) of Short term Borrowings | 1,21,37,556.48 | (6,10,79,426.08) |
| | Increase in/(Repayment) of Long term Borrowings | 60,77,310.79 | 81,34,994.09 |
| | Increase/ (Decrease) in share capital | - | - |
| | Increase/ (Decrease) in share premium | - | - |
| | Other Inflows/ (Outflows) of cash | (89,60,000.00) | - |
| | **Net cash used in Financing Activities (C** | **(97,36,085.44)** | **(7,71,40,413.80)** |
| D | **Net Increase/(Decrease) in cash & cash equivalents (A+B+C)** | **6,89,93,040.51** | **5,03,77,703.50** |
| E | Cash & Cash equivalents at beginning of period | 10,42,47,300.46 | 5,38,69,596.96 |
| F | Cash & Cash equivalents at end of period | 17,32,40,340.97 | 10,42,47,300.46 |
| G | **Net Increase/(Decrease) in cash & cash equivalents (F-E)** | **6,89,93,040.51** | **5,03,77,703.50** |

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 27th April 2022
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.
4. The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

**For KALRA RAI AND ASSOCIATES**
Chartered Accountants
**(FRN: 008859N)**

**LAJPAT RAI KALRA**
**PARTNER**
**Membership No. : 087438**
**Place : Chandigarh**
**Date : 27/04/2022**

**For and on Behalf of Board of Directors**

**RAHUL BATRA**
**MANAGING DIRECTOR**
**DIN : 02229234**

GSTIN. 04AAFFK0327H1ZT

KALRA RAI & ASSOCIATES
A Peer Review Firm
CHARTERED ACCOUNTANTS

M : +91-98880-66743
Phone - 0172-4640667
E-mail : kalrarai@gmail.com
kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**Independent Auditor's Report on Audited standalone half yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**TO THE BOARD OF DIRECTORS OF,**

Beta Drugs Limited
Village Nandpur, Lodhimajra ROad
Baddi Distt Solan
H.P.-174101

**Report on the audit of the Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone half yearly financial results of **Beta Drugs Limited** (the company) for the half year ended **31st March, 2022** and the year to date results for the period from **1st April, 2021** to **31st March, 2022** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the half year ended **31st March, 2022** as well as the year to date results for the period from **1st April, 2021** to **31st March, 2022**.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008859N

Branch Office Mohali :-
Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082
EMAIL : kalrarai@rediffmail.com
Branch Office Delhi :-
I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803
EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173

## Management's Responsibilities for the Standalone Financial Results

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to

KALRA & ASSOCIATES Chartered Accountants FRN 008859N

the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For KALRA RAI & ASSOCIATES.**
**Chartered Accountants**
**(Firm's Registration No. 008859N)**

KALRA RAI & ASSOCIATES
Chartered Accountants
FRN 008859N

**LAJPAT RAI KALRA**
**(Partner)**
**(Membership Number: 087438)**
**UDIN: 22087438AHWZNO3962**

**Place: Chandigarh**
**Date: 27/04/2022**

# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

**Audited Standalone Financial Results for the year ended on 31st March' 2022**

| Particulars | 6 Months Ended on 31/03/2022 (Audited) | Year Ended on 31/03/2022 (Audited) | 6 Months Ended on 31/03/2021 (Audited) | Year Ended on 31/03/2021 (Audited) |
|---|---|---|---|---|
| I. Revenue From Operations | 65,31,73,676.05 | 1,24,84,68,429.04 | 44,63,57,677.41 | 79,45,64,118.69 |
| II. Other Income | 34,78,294.00 | 85,78,565.00 | 34,12,498.10 | 61,12,387.36 |
| **III. Total Revenue (I+II)** | **65,66,51,970.05** | **1,25,70,46,994.04** | **44,97,70,175.51** | **80,06,76,506.05** |
| IV. Expenses | | | | |
| a) Cost of Materials Consumed | 36,14,03,627.57 | 69,86,31,569.86 | 25,66,76,258.03 | 44,83,14,667.04 |
| b) Purchase of Stock-in-Trade | - | - | - | - |
| c) (Increase)/Decrease in Stock of Finished Goods/WIP | 1,07,45,990.06 | 86,08,723.73 | (1,34,58,137.09) | (1,38,29,315.43) |
| d) Other Manufacturing expenses | 6,04,95,760.96 | 12,12,36,387.05 | 5,24,18,507.65 | 9,40,49,150.51 |
| e) Employee benefit expenses | 5,12,33,463.17 | 8,72,46,721.07 | 3,45,34,814.10 | 6,05,62,713.10 |
| f) Finance Costs | 20,07,927.29 | 41,22,446.22 | 37,90,989.31 | 77,27,028.50 |
| g) Depreciation & amortisation expenses | 2,98,22,585.21 | 5,46,77,970.56 | 2,76,91,728.96 | 5,26,74,004.01 |
| h) Other expenses | 4,30,25,804.62 | 8,09,06,768.85 | 2,97,54,825.00 | 5,23,66,973.56 |
| **Total Expenses** | **55,87,35,158.88** | **1,05,54,30,587.34** | **39,14,08,985.96** | **70,18,65,221.29** |
| **V. Profit before exceptional and extraordinary items and tax (III-IV)** | **9,79,16,811.17** | **20,16,16,406.70** | **5,83,61,189.55** | **9,88,11,284.76** |
| **VI.Exceptional Items** | - | - | - | - |
| **VII. Profit before extraordinary items and tax (V-VI)** | **9,79,16,811.17** | **20,16,16,406.70** | **5,83,61,189.55** | **9,88,11,284.76** |
| **VIII.Extraordinary Items** | | | | |
| **IX. Profit before tax (VII-VIII)** | **9,79,16,811.17** | **20,16,16,406.70** | **5,83,61,189.55** | **9,88,11,284.76** |
| **X.Tax Expenses** | | | | |
| a) Current year tax | 2,96,11,298.07 | 6,15,05,789.80 | 2,17,86,690.63 | 3,30,23,449.66 |
| b) MAT credit/Deferred tax | (7,47,958.50) | (23,54,223.02) | (25,84,659.95) | (39,89,920.45) |
| **XI. Profit (Loss) for the period from continuing operations (IX-X)** | **6,90,53,471.60** | **14,24,64,839.93** | **3,91,59,158.87** | **6,97,77,755.55** |
| **XII.Profit (Loss) from discounting operations** | | | | |
| **XIII. Tax expenses of dicounting operations** | | | | |
| **XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)** | - | - | - | - |
| **XV. Net Profit/(Loss) for the period (XI+XIV)** | **6,90,53,471.60** | **14,24,64,839.93** | **3,91,59,158.87** | **6,97,77,755.55** |
| **XVI. Earning per share** | | | | |
| a) Basic | 7.18 | 14.82 | 4.07 | 7.26 |
| b) Diluted | 7.18 | 14.82 | 4.07 | 7.26 |
| **XVIII. Paid up equity share captial** | **9,61,37,900.00** | **9,61,37,900.00** | **9,61,37,900.00** | **9,61,37,900.00** |
| **Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year** | **67,84,78,459.70** | **67,84,78,459.70** | **53,80,30,641.46** | **53,80,30,641.46** |

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 27th April 2022.
2 The company is engaged in single business segment i.e. Pharmaceuticals.
3 Figures are regrouped/rearranged, wherever considered necessary.
4 The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
UDIN: 22087438AHWZNO3962
Place : Chandigarh
Date : 27/04/2022

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO

# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

**Standalone Statement of Assets & Liabilities for the year ended on 31st March' 2022**

| Particulars | As at 31st March' 2022<br>Amount in Rs. | As at 31st March' 2021<br>Amount in Rs. |
|---|---|---|
| **1. EQUITY AND LIABILITIES** | | |
| **(A) Shareholder's Funds** | | |
| (a) Share Capital | 9,61,37,900.00 | 9,61,37,900.00 |
| (b) Reserves and Surplus | 67,84,78,459.70 | 53,80,30,641.46 |
| (c)Money recevied against share warrants | | |
| **Sub-total-Shareholders' funds** | **77,46,16,359.70** | **63,41,68,541.46** |
| **(B) Non- Current Liabilities** | | |
| (a) Long-term borrowings | 5,15,08,245.00 | 3,38,63,312.69 |
| (b) Deferred tax liabilities (Net) | - | - |
| (c) Other Long term liabilities | 1,43,94,249.36 | 1,02,09,629.04 |
| (d) Long term Provisions | 99,85,505.00 | 79,99,532.00 |
| **Sub-total-Non- current liabilities** | **7,58,87,999.36** | **5,20,72,473.73** |
| **(C) Current Liabilities** | | |
| (a) Short-term borrowings | - | 50,08,697.47 |
| (b) Trade Payable | 19,66,28,778.34 | 13,24,39,138.46 |
| (c) Other current liabilities | 4,24,63,374.95 | 3,28,87,432.84 |
| (d) Short-term provisions | 1,93,74,536.16 | 57,45,458.38 |
| **Sub-total-current liabilites** | **25,84,66,689.45** | **17,60,80,727.15** |
| **TOTAL - EQUITY AND LIABILITIES** | **1,10,89,71,048.51** | **86,23,21,742.35** |
| **2. ASSETS** | | |
| **(A) Non-current assets** | | |
| (a) Fixed assets | | |
| (i) Property, Plant & Equipment | 32,92,13,999.85 | 27,44,63,684.91 |
| (ii) Intangible assets | 1,13,57,083.35 | 56,43,868.43 |
| (iii) Capital work-in-progress | - | 1,90,28,682.41 |
| (b) Non Current Investments | 6,54,29,905.49 | 6,54,29,905.49 |
| (c) Long Term Loan & Advance | 6,88,84,261.86 | 3,35,04,481.00 |
| (d) Other Non Current Assets | 5,00,000.00 | 2,50,69,279.69 |
| (e) Deferred tax Assets | 60,18,494.61 | 36,64,271.59 |
| **Sub-total-Non-current assets** | **48,14,03,745.16** | **42,68,04,173.52** |
| **(B) Current Assets** | | |
| (a) Inventories | 8,47,01,656.11 | 7,69,50,318.81 |
| (b) Trade receivable | 31,35,42,295.25 | 20,80,80,401.12 |
| (c) Cash and bank balance | 15,58,06,654.01 | 8,26,61,552.81 |
| (d) Short-term loan and advances | 1,90,25,193.98 | 1,99,12,178.91 |
| (e) Other current assets | 5,44,91,504.00 | 4,79,13,117.18 |
| **Sub-total-current assets** | **62,75,67,303.35** | **43,55,17,568.83** |
| **TOTAL - ASSETS** | **1,10,89,71,048.51** | **86,23,21,742.35** |

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.
4. The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

**For KALRA RAI AND ASSOCIATES**
Chartered Accountants
**(FRN : 008859N)**

KALRA RAI & ASSOCIATES Chartered Accountants FRN 008859

**LAJPAT RAI KALRA**
**PARTNER**
**Membership No. : 087438**
**UDIN: 22087438AHWZNO3962**
**Place : Chandigarh**
**Date : 27/04/2022**

**For and on Behalf of Board of Directors**

**RAHUL BATRA**
**MANAGING DIRECTOR**
**DIN : 02229234**

# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Standalone Cashflow Statement for the half year ended on 31st March' 2022**

| | Particulars | As at 31 March' 2022 | As at 31 March' 2021 |
|---|---|---|---|
| | | Amount in Rs. | Amount in Rs. |
| A | **CASHFLOW FROM OPERATING ACTIVITIES** | | |
| | **Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)** | **20,16,16,406.70** | **9,88,11,284.76** |
| | Adjustments for non Cash/Non trade items: | | |
| | Depreciation & Amortization Expenses | 5,46,77,970.56 | 5,26,74,004.01 |
| | Finance Cost | 41,22,446.22 | 77,27,028.50 |
| | Interest received | (63,30,992.00) | (56,99,508.36) |
| | Other inflows/(outflows) of cash | (2,13,21,459.33) | (1,47,34,377.53) |
| | **Operating profits before Working Capital Changes** | **23,27,64,372.15** | **13,87,78,431.39** |
| | **Adjusted For:** | | |
| | (Increase)/Decrease in trade receivables | (10,54,61,894.13) | 10,07,137.99 |
| | Increase/(Decrease) in trade payables | 6,41,89,639.88 | 3,97,70,385.12 |
| | (Increase)/Decrease in inventories | (77,51,337.30) | (1,59,57,583.44) |
| | Increase/(Decrease) in other current liabilities | 95,75,942.11 | (3,58,93,124.78) |
| | (Increase)/Decrease in short term loans and advances | 8,86,984.93 | (12,82,135.30) |
| | (Increase)/Decrease in other current assets | (65,78,386.82) | (1,04,35,192.74) |
| | **Net Changes in working capital** | **(4,51,39,051.33)** | **(2,27,90,513.15)** |
| | **Net cashflow from Operating Activities (A)** | **18,76,25,320.81** | **11,59,87,918.24** |
| B | **CASHFLOW FROM INVESTING ACTIVITIES** | | |
| | Purchase of tangible/intangible assets | (9,61,12,818.00) | (3,43,42,726.02) |
| | Interest received | 63,30,992.00 | 56,99,508.36 |
| | Cash used for Non Current Investments | | (42,69,312.87) |
| | Cash used for Long Term Loans/Advances | (3,73,96,802.55) | 13,76,818.00 |
| | **Net cash used in Investing Activities (B)** | **(12,71,78,628.55)** | **(3,15,35,712.53)** |
| C | **CASHFLOW FROM FINANCING ACTIVITIES** | | |
| | Finance Cost | (41,22,446.22) | (77,27,028.50) |
| | Increase in/(Repayment) of Short term Borrowings | (50,08,697.47) | (3,46,83,254.35) |
| | Increase in/(Repayment) of Long term Borrowings | 2,18,29,552.63 | (9,93,601.68) |
| | Increase/ (Decrease) in share capital | - | - |
| | Increase/ (Decrease) in share premium | - | - |
| | Other Inflows/ (Outflows) of cash | - | - |
| | **Net cash used in Financing Activities (C** | **1,26,98,408.94** | **(4,34,03,884.53)** |
| D | **Net Increase/(Decrease) in cash & cash equivalents (A+B+C)** | **7,31,45,101.20** | **4,10,48,321.18** |
| E | Cash & Cash equivalents at beginning of period | 8,26,61,552.81 | 4,16,13,231.63 |
| F | Cash & Cash equivalents at end of period | 15,58,06,654.01 | 8,26,61,552.81 |
| G | **Net Increase/(Decrease) in cash & cash equivalents (F-E)** | **7,31,45,101.20** | **4,10,48,321.18** |

1. The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 27th April 2022.
2. The company is engaged in single business segment i.e. Pharmaceuticals.
3. Figures are regrouped/rearranged, wherever considered necessary.
4. The above results for the half year ended 31st March, 2022 being the balancing figure between the audited figures in respect of the full financia year ended 31st March, 2022 and the published unaudited year to date figure of the first half of the financial year.

**For KALRA RAI AND ASSOCIATES**
Chartered Accountants
**(FRN : 008859N)**

Chartered Accountants FRN 008859N

**LAJPAT RAI KALRA**
**PARTNER**
**Membership No. : 087438**
**Place : Chandigarh**
**Date : 27/04/2022**

**For and on Behalf of Board of Directors**

**RAHUL BATRA**
**MANAGING DIRECTOR**
**DIN : 02229234**

# BETA DRUGS LIMITED

**BDL/PKL/SEC/2022**
**27th April, 2022**

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/l, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

**SYMBOL-BETA**

**Sub:** Declaration Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015

Dear Sir/Madam

In accordance with Regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we hereby declare that M/s Kalra Rai & Associates, Chartered Accountant (Firm Registration Number 008859N), Statutory Auditors of the Company have issued an Auditors Report with unmodified opinion on Standalone and Consolidated Audited Financial Results of the Company for the half year and year ended 31.03.2022 approved at the Board Meeting held on 27th April, 2022.

Kindly take the same on record.

Thanking You

Your's faithfully
For Beta Drugs Ltd.

Rahul Batra
Managing Director
DIN NO. 02229234